Familial cancer and developmental dyslexia: an observational pilot study

Area of Science:

• Neuroscience
• Genetics
• Immunology

Background:

• Developmental dyslexia has a partial genetic basis.
• Platelet-activating factor (PAF) is a proinflammatory mediator involved in cell damage and immune responses.
• Elevated PAF levels may offer protection against cancer development.

Purpose of the Study:

• To investigate the hypothesis that elevated platelet-activating factor (PAF) contributes to the etiology of developmental dyslexia.
• To test the prediction that dyslexia is negatively associated with a family history of cancer, based on the PAF hypothesis.
• To explore the relationship between family cancer history and reading/spelling abilities in children.

Main Methods:

• A cohort of children with (n=163) and without (n=154) developmental dyslexia was recruited.
• Participants were categorized based on family history of cancer (n=152 with, n=165 without).
• Standard psychometric tests, including British Ability Scales subtests, were administered to assess cognitive abilities.

Main Results:

• A lower proportion of children with dyslexia (38%) had a family history of cancer compared to controls (58.4%).
• A 'dose' effect was observed: children with more relatives diagnosed with cancer exhibited improved reading and spelling performance.
• These findings suggest a negative association between dyslexia and family cancer history.

Conclusions:

• Children with a genetic predisposition to dyslexia and a family history of cancer demonstrate enhanced reading and spelling abilities.
• The results support the platelet-activating factor (PAF) hypothesis regarding the etiology of developmental dyslexia.
• A family history of cancer may be a protective factor against dyslexia, potentially mediated by PAF levels.